Submitted by Anonymous (not verified) on 29 August 2023 - 12:52
Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Arthritis, Rheumatoid, Date of authorisation: 16/12/2019, Revision: 17, Status: Authorised
Source: